DE3751907D1 - Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie - Google Patents

Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie

Info

Publication number
DE3751907D1
DE3751907D1 DE3751907T DE3751907T DE3751907D1 DE 3751907 D1 DE3751907 D1 DE 3751907D1 DE 3751907 T DE3751907 T DE 3751907T DE 3751907 T DE3751907 T DE 3751907T DE 3751907 D1 DE3751907 D1 DE 3751907D1
Authority
DE
Germany
Prior art keywords
ischemia
protect against
tissue damage
against tissue
injectable drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751907T
Other languages
English (en)
Other versions
DE3751907T2 (de
Inventor
Robert L Hunter
Alexander Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/045,459 external-priority patent/US4801452A/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE3751907D1 publication Critical patent/DE3751907D1/de
Publication of DE3751907T2 publication Critical patent/DE3751907T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE3751907T 1986-05-15 1987-05-08 Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie Expired - Fee Related DE3751907T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86358286A 1986-05-15 1986-05-15
US4388887A 1987-04-29 1987-04-29
US07/045,459 US4801452A (en) 1986-05-15 1987-05-07 Fibrinolytic composition

Publications (2)

Publication Number Publication Date
DE3751907D1 true DE3751907D1 (de) 1996-10-17
DE3751907T2 DE3751907T2 (de) 1997-04-03

Family

ID=27366409

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3751907T Expired - Fee Related DE3751907T2 (de) 1986-05-15 1987-05-08 Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie
DE3789196T Expired - Fee Related DE3789196T2 (de) 1986-05-15 1987-05-08 Fibrinolytische zusammensetzung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3789196T Expired - Fee Related DE3789196T2 (de) 1986-05-15 1987-05-08 Fibrinolytische zusammensetzung.

Country Status (11)

Country Link
EP (3) EP0266419B1 (de)
JP (9) JPH0610139B2 (de)
KR (1) KR880701107A (de)
AT (1) ATE142502T1 (de)
AU (1) AU599392B2 (de)
BR (1) BR8707308A (de)
DE (2) DE3751907T2 (de)
DK (1) DK10888A (de)
FI (1) FI94928C (de)
IL (1) IL82519A (de)
WO (1) WO1987006836A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8503097A (nl) * 1985-11-11 1987-06-01 Leuven Res & Dev Vzw Geneesmiddel met thrombolytische werking.
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
HU207349B (en) * 1988-04-04 1993-03-29 Gen Hospital Corp Process for producing pharmaceutical composition for quickly eliminating trombus
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH05501855A (ja) * 1989-05-17 1993-04-08 リサーチ、コーポレーション、テクノロジーズ、インコーポレーテッド 哺乳動物における血栓症の治療に関する方法及び組成物
JP2647556B2 (ja) 1991-03-19 1997-08-27 サイトアーレクス・コーポレーシヨン 改良された生物学的活性を有するポリオキシプロピレン／ポリオキシエチレン共重合体類
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
GB2289069B (en) * 1994-03-31 1997-12-17 Toppan Moore Kk Microcapsule-containing oil-based coating liquid,ink,coated sheet,and method of prepring the same
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
KR100241202B1 (ko) * 1995-09-12 2000-02-01 니시무로 타이죠 전류미러회로
JP2001515345A (ja) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対する抗体を用いてフィブリン溶解を増進するための組成物と方法
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
EP1311154A2 (de) * 2000-08-25 2003-05-21 Organ Recovery Systems, Inc. Verfahren zur thrombolytischen organbehandlung und -wiederherstellung
DE10314083A1 (de) * 2003-03-28 2004-10-14 Mcs Micro Carrier Systems Gmbh Produkt zum Schutz von Blutgefäßen
WO2006035673A1 (ja) * 2004-09-28 2006-04-06 Japan Science And Technology Agency 虚血性心臓傷害の新保護法
US8211817B2 (en) 2006-09-11 2012-07-03 Tosoh Corporation Fused silica glass and process for producing the same
US9206410B2 (en) 2009-03-03 2015-12-08 Grifols Therapeutics Inc. Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom
JP6336392B2 (ja) * 2012-09-08 2018-06-06 株式会社オーガンテクノロジーズ 移植のための臓器又は組織の長期維持方法
WO2016007537A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
GB201511207D0 (en) * 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
US20190104718A1 (en) * 2017-10-09 2019-04-11 Efran Cano Entry barrier

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie

Also Published As

Publication number Publication date
WO1987006836A1 (en) 1987-11-19
JPH0610139B2 (ja) 1994-02-09
JPH0616565A (ja) 1994-01-25
JPH0757730B2 (ja) 1995-06-21
KR880701107A (ko) 1988-07-25
JPH0648951A (ja) 1994-02-22
FI880163A0 (fi) 1988-01-14
JPH0735336B2 (ja) 1995-04-19
JPH0616562A (ja) 1994-01-25
EP0451880A2 (de) 1991-10-16
ATE142502T1 (de) 1996-09-15
JPH01500592A (ja) 1989-03-01
AU599392B2 (en) 1990-07-19
FI94928B (fi) 1995-08-15
DE3751907T2 (de) 1997-04-03
BR8707308A (pt) 1988-09-13
EP0498470A3 (en) 1993-03-03
JPH0624993A (ja) 1994-02-01
DE3789196D1 (de) 1994-04-07
EP0498470A2 (de) 1992-08-12
EP0451880A3 (en) 1991-12-27
JPH0616571A (ja) 1994-01-25
EP0498470B1 (de) 1996-09-11
FI880163A (fi) 1988-01-14
EP0266419A4 (de) 1989-03-15
JPH0735338B2 (ja) 1995-04-19
JPH06100454A (ja) 1994-04-12
DE3789196T2 (de) 1994-06-16
IL82519A (en) 1992-05-25
EP0266419A1 (de) 1988-05-11
DK10888D0 (da) 1988-01-11
AU7484087A (en) 1987-12-01
JPH0616567A (ja) 1994-01-25
FI94928C (fi) 1995-11-27
JPH0640924A (ja) 1994-02-15
JPH0735337B2 (ja) 1995-04-19
JPH0653685B2 (ja) 1994-07-20
DK10888A (da) 1988-03-11
EP0266419B1 (de) 1994-03-02

Similar Documents

Publication Publication Date Title
DE3751907D1 (de) Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie
NO891082D0 (no) Fremgangsmaate for fremstilling av peptidforbindelser.
AU639514B2 (en) Bicyclam derivatives
HUT67285A (en) Cyclic ureas and analogues and pharmaceutical compositions
KR960703567A (ko) 약제학적 조성물(Pharmaceutical composition)
CA2102778A1 (fr) Nouvelles compositions a base de derives de la classe des taxanes
KR940003965A (ko) 인체 면역 결핍 비루스(hiv)프로테아제의 활성을 억제할수 있는 펩티드, 그의 제조방법, 및 그의 치료적 용도
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
DE69327330D1 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
FI921522A (fi) Pyrazolopyridinfoerening och foerfarande foer dess framstaellning
KR910700230A (ko) 신규 히드록실아민 유도체
GB1502873A (en) Pharmaceutical compositions with ulcer healing activity
IE42763L (en) Tertiary amino alkylphenyl ether compounds, anesthetics
SE7503952L (sv) Sett att framstella spasmolytiska foreningar.
FR2409996A1 (fr) 15-epi-prostacycline et analogues, utiles notamment comme agents antithrombotiques et thrombolytiques et leur procede de preparation
GB1424432A (en) Pharmaceutical compositions
GB1508338A (en) Pharmaceutical compositions
IT1204778B (it) Formulazioni farmaceutiche iniettabili di principi attivi ad attivita' anestetica generale
AR040650A1 (es) Polipeptido t 1249 pegilado, inhibitorio de la infeccion por h.i.v.
JPS57126461A (en) Novel guanidino compound and its preparation
JPS5535069A (en) Tetrapeptide derivative
TR200102196T2 (tr) Mono-asiloksi aralkil nöromuskular relaksanları.
ES357658A1 (es) Procedimiento para la preparacion de esteres del acido car-bamico.
JPS5675427A (en) Antiarteriosclerotic agent containing procainamide hydrochloride
JPS5651494A (en) 1-(aminoalkanoyl)aminoethylphosphonic acid derivative

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee